99 related articles for article (PubMed ID: 19854294)
1. Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs.
Helleman J; Jansen MP; Burger C; van der Burg ME; Berns EM
Int J Biochem Cell Biol; 2010 Jan; 42(1):25-30. PubMed ID: 19854294
[TBL] [Abstract][Full Text] [Related]
2. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
Helleman J; Smid M; Jansen MP; van der Burg ME; Berns EM
Gynecol Oncol; 2010 May; 117(2):170-6. PubMed ID: 20132968
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs in ovarian cancer biology and therapy resistance.
van Jaarsveld MT; Helleman J; Berns EM; Wiemer EA
Int J Biochem Cell Biol; 2010 Aug; 42(8):1282-90. PubMed ID: 20083225
[TBL] [Abstract][Full Text] [Related]
4. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
5. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
6. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
7. Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells.
Buys TP; Chari R; Lee EH; Zhang M; MacAulay C; Lam S; Lam WL; Ling V
Genes Chromosomes Cancer; 2007 Dec; 46(12):1069-79. PubMed ID: 17726699
[TBL] [Abstract][Full Text] [Related]
8. Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors.
Yamada SD; Baldwin RL; Karlan BY
Gynecol Oncol; 1999 Oct; 75(1):72-7. PubMed ID: 10502429
[TBL] [Abstract][Full Text] [Related]
9. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP
Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661
[TBL] [Abstract][Full Text] [Related]
10. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
12. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
13. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients.
Kudoh K; Takano M; Koshikawa T; Hirai M; Yoshida S; Mano Y; Yamamoto K; Ishii K; Kita T; Kikuchi Y; Nagata I; Miwa M; Uchida K
Clin Cancer Res; 1999 Sep; 5(9):2526-31. PubMed ID: 10499629
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma.
Francis-Thickpenny KM; Richardson DM; van Ee CC; Love DR; Winship IM; Baguley BC; Chenevix-Trench G; Shelling AN
Br J Cancer; 2001 Sep; 85(5):687-91. PubMed ID: 11531253
[TBL] [Abstract][Full Text] [Related]
15. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
16. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta.
Rodriguez GC; Haisley C; Hurteau J; Moser TL; Whitaker R; Bast RC; Stack MS
Gynecol Oncol; 2001 Feb; 80(2):245-53. PubMed ID: 11161867
[TBL] [Abstract][Full Text] [Related]
17. Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
Hempel N; How T; Dong M; Murphy SK; Fields TA; Blobe GC
Cancer Res; 2007 Jun; 67(11):5231-8. PubMed ID: 17522389
[TBL] [Abstract][Full Text] [Related]
18. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.
Lu L; Katsaros D; de la Longrais IA; Sochirca O; Yu H
Cancer Res; 2007 Nov; 67(21):10117-22. PubMed ID: 17974952
[TBL] [Abstract][Full Text] [Related]
20. The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer.
Sellar GC; Watt KP; Li L; Nelkin BD; Rabiasz GJ; Porteous DJ; Smyth JF; Gabra H
Int J Oncol; 2002 Nov; 21(5):929-33. PubMed ID: 12370737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
